지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.1
- 수록면
- 61 - 87 (27page)
- DOI
- 10.5217/ir.2022.00007
이용수
초록· 키워드
오류제보하기
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin α4β7 and anti-interleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Second Korean guidelines for the management of ulcerative colitis
Intestinal research
2017 .01
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Intestinal research
2023 .04
-
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Gut and Liver
2020 .01
-
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Intestinal research
2019 .01
-
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease
Intestinal research
2017 .01
-
Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
대한류마티스학회지
2020 .01
-
염증장질환의 치료: 생물학적제제 및 새로운 치료법을 중심으로
대한의사협회지
2021 .09
-
Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018
Intestinal research
2021 .01
-
Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior
Intestinal research
2019 .01
-
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Immune Network
2017 .02
-
Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
Journal of Korean Medical Science
2021 .12
-
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Intestinal research
2024 .07
-
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Intestinal research
2020 .01
-
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
Gut and Liver
2021 .01
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis
Intestinal research
2016 .01
-
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Intestinal research
2021 .01
-
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Intestinal research
2021 .01
-
Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
Gut and Liver
2017 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0